Successful innovation requires a holistic risk-based approach beyond financial, infrastructure and manpower investments
IN AN interview with private-equity investor David Rubenstein, chief executive officer of Novartis Dr Vasant Narasimhan spoke about the potential and possibilities of pharmaceuticals in a fiercely competitive industry.





